%0 Generic
%A Vivas A.A
%A Machola D.A.L
%A Rincón E.H.H
%A Jurado N.J.P
%A Navarrete M.P.D.P
%A Monsalve W.H.V
%A Morales J.D.Á
%A Delgado P.A.V
%8 2024
%@ 3674762
%U http://hdl.handle.net/10818/62195
%X Introduction: Treatment to reduce mortality with dexamethasone for ten days in oxygen-requiring COVID-19 patients (RECOVERY protocol) may have the adverse effect of hyperglycemia, a factor associated with morbidity and mortality, as well as a history of type 2 diabetes mellitus. Objective: Describe the glycemic behavior in patients with a history of type 2 diabetes undergoing the RECOVERY protocol during their hospitalization for COVID-19. M ethodology: A descriptive and cross-sectional study obtained data from medical records of patients between 18 and 80 years old with a history of type 2 diabetes and COVID-19 infection hospitalized with the RECOVERY protocol from June 2020 to June 2022. Results: 41 subjects with a mean age of 62.1±10.3 years, where 39 % had blood glucose levels higher than 180 mg/ dL, the median glucose on admission was 159 mg/ dL, 170.5 mg/dL, after three days 170,5 mg/dL, seven days of 177 mg/dL and 146 mg/dL at discharge. Those under 65 years of age, those stratified with CURB of 2 or more, had higher blood glucose on days 3 and 7. Conclusions: During the administration of dexamethasone, blood glucose levels on days 3 and 7 were higher. Stricter blood glucose monitoring is required, especially on the aforementioned days, in patients with diabetes undergoing the RECOVERY protocol. © 2024 National Academy of Medicine. All rights reserved.
%I Gaceta Medica de Caracas
%T Covid-19 and glucometric variation in type 2 diabetes during the recovery protocol
%R 10.47307/GMC.2024.132.2.3
%~ Intellectum